IHCU:LSE:LSE-iShares S&P 500 Health Care Sector UCITS ETF USD (Acc) GBP (GBX)

ETF | Others |

Last Closing

USD 849.5

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.05M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-06 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

N/A

USD 640.06B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

N/A

USD 640.06B
0R1I:LSE NVIDIA Corp.

N/A

USD 618.20B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

N/A

USD 266.08B
PRJU:LSE Amundi Index Solutions - Amund..

N/A

USD 259.48B
0QZO:LSE 0QZO

N/A

USD 258.54B
0QZ3:LSE Qualcomm Inc.

N/A

USD 202.26B
0R24:LSE Intel Corp.

N/A

USD 196.14B

ETFs Containing IHCU:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.05% 57% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.05% 56% F 59% D-
Trailing 12 Months  
Capital Gain -4.25% 31% F 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.25% 29% F 42% F
Trailing 5 Years  
Capital Gain 52.41% 55% F 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 52.41% 51% F 62% D
Average Annual (5 Year Horizon)  
Capital Gain 10.46% 65% D 69% C-
Dividend Return 10.46% 64% D 68% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.76% 71% C- 84% B
Risk Adjusted Return 119.36% 96% N/A 98% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike